Homocysteine ELISA kit

Name: Homocysteine ELISA kit
SKU: DEIABL3
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

plasma, serum

Species Reactivity

Human

Detection Method

sELISA

Intended Use

Homocysteine ELISA kit is intended for the Quantitative Determination of total Lhomocysteine in plasma or serum. For In Vitro Research Use Only (RUO).

Storage

The microtiter well plate and all other reagents are stable at 2-8°C until the expiration date printed on the label. Store microplate sealed and dessicated in the clip bag provided. Shelf life of the unopended test kit is 18 months from day of production. Avoid exposure of the kit to temperatures exceeding 37 °C as this may denature the enzymes.

Precision

Detection Range

The calibrator range is from 2.0 to 50.0 μmol/L.

Detection Limit

The quantification limit of Homocysteine ELISA kit is 1.0 μmol/L with a CV < 20%.

General Description

Homocysteine is a thiol-containing amino acid produced by the intracellular demethylation of methionine. Homocysteine is metabolised to either cysteine or to methionine. Homocysteine circulates in plasma mostly in its oxidised form bound to proteins and is measured as total homocysteine, (tHcy), the sum of free and protein bound. Severely elevated concentrations of tHcy are found in subjects with homocystinuria, a rare genetic disorder of the enzymes involved in the metabolism of homocysteine. Patients with homocystinuria exhibit mental retardation, early arteriosclerosis and arterial and venous thromboembolism. Other less severe genetic defects which lead to moderately elevated levels of homocysteine are also found. Drugs such as methotrexate, carbamazepine, phenytoin, nitrous oxide and penicillamine interfere with the Hcy metabolism and may give elevated levels of Hcy.

Standard Curve

Citations

Have you cited DEIABL3 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Design strategy and bioimaging of small organic molecule multicolor fluorescent probes

SCIENCE CHINA-CHEMISTRY

Authors: Huang, Yongfei; Zhang, Yongbin; Huo, Fangjun; Wen, Ying; Yin, Caixia

Abstract

Multicolor fluorescent probes based on small organic molecules have the advantages of low cost, good biocompatibility, easily modifiable molecular structures and adjustable fluorescence performance. In addition, small molecule multicolor fluorescent probes generally undergo multi-site or multi-step reactions, which means that they can be used for the specific detection of structurally similar substances in complex bio-systems. In this review, we focus on the design and application of multicolor fluorescent probes based on small organic molecules: single fluorophores with multiple reaction sites, multiple fluorophores with single reaction sites, or multiple fluorophores with multiple reaction sites. Moreover, a design strategy for multicolor fluorescent probes and its application in biological imaging are also summarized, providing a systematic plan for future research on fluorescent probes functionalized by small organic molecules. It will also play an important role in the development of additional functions for small organic molecule fluorescent probes.

Evaluation of serumFoxO1,mTORC1,IGF-1,IGFBP-3 levels, and metabolic syndrome components in patients with acne vulgaris: A prospective case-control study

DERMATOLOGIC THERAPY

Authors: Karabay, Ezgi Aktas; Saltik, Zeynep Alara; Demirel, Ozlem Unay

Abstract

Recently, insulin-like growth factor-1 (IGF-1), forkhead box transcription factor (Fox) O1, and mechanistic target of rapamycin complex 1 (mTORC1) signaling have been introduced as key elements in acne pathogenesis. The aim of this study is to investigate the relationship between serum levels of IGF-1, insulin-like growth factor binding protein-3 (IGFBP-3), FoxO1 and mTORC1, and the components of metabolic syndrome (MS) and AV. This prospective case-control study was carried out on 89 participants, including 49 AV patients and 40 controls. The serum levels of IGF-1, IGFBP-3, insulin, FoxO1, and mTORC1 were measured along with the components of MS. The blood pressure (BP) measures were significantly higher in the AV patients than in the controls (P= .001). The mean high-density lipoprotein cholesterol (HDL-C) levels were significantly lower in the AV patients than in the controls (P= .040). The numbers of accompanying MS components were significantly higher in the AV patients than in the controls (P= .001). The IGFBP-3 levels were significantly higher in the AV patients than in the controls (P= .02). The IGF-1, mTORC1, and FoxO1 levels were higher in the AV patients than in the controls; neither were statistically significant (P= .093,P= .741, andP= .564, respectively). The higher BP and IGFBP-3 levels, the lower HDL-C levels and the common presence of MS components demand caution in terms of new therapeutic strategies and possible associated comorbidities.